Vasomedical Proves Itself A Company To Watch On The Fast Track to Growth

Vasomedical, Inc.  (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, has positioned itself for growth and its future is promising considering its recent developments. The company announced its restructure to further align its business management structure and long term growth strategy. The Company will now be operating through three wholly-owned subsidiaries. Vaso Diagnostics, Inc.;VasoHealthcare; and Vasomedical Global Corp.  Vasomedical Solutions, Inc. has been formed to manage and coordinate its EECP® therapy business as well as other medical equipment operations.

Vasomedical also has appointed Michael J. Beecher, as its Chief Financial Officer. Jonathan P. Newton, the company’s previous Chief Financial Officer, will now assume the role of Vice President of Finance and Controller. During his many years as a financial executive, Mr. Beecher has accumulated extensive experience in private and public financings, mergers and acquisitions as well as in the integration of international and domestic operations. Welcoming Mr. Beecher to Vasomedical, President and CEO Jun Ma stated, “Together with the acquisition of the two companies in China, Life Enhancement Technology Limited and Biox Instruments Co. Ltd., the restructure of the Company is another important element of our global growth strategy. The timely addition of Mr. Beecher brings additional resources and valuable expertise to our management team and will help us move forward with our plans for future growth and expansion.”

Click here for full press release.

The comments are closed.